Literature DB >> 25390061

Use of port-a-cath in cancer patients: a single-center experience.

Philomena Charlotte D'Souza1, Shiyam Kumar, Annupam Kakaria, Rashid Al-Sukaiti, Khawaja Farhan Zahid, Muhammad Furrukh, Ikram A Burney, Mansour S Al-Moundhri.   

Abstract

INTRODUCTION: Central venous catheters play an important role in the management of cancer patients. Different types of devices are associated with different patterns of complications. We report on the pattern of use and rate of complications of port-a-caths in patients diagnosed with malignant cancer at a single institution.
METHODOLOGY: The data were collected retrospectively from patients who received the treatment for solid tumors or lymphoma through a port-a-cath at the Sultan Qaboos University Hospital (SQUH) between January 2007 and February 2013.
RESULTS: A total of 117 port-a-caths were inserted in 106 patients. The majority (86; 73.5%) were implanted by an interventional radiologist, and the right internal jugular vein was accessed in 79 (67.5%) patients. Mean catheter indwelling time was 354 (range 3-1,876) days for all patients, 252 (3-1,876) and 389 days (13-1,139) for patients with and without complications, respectively. Thirty (25.6%) port-a-caths were removed prematurely, mainly due to infectious complications, while 17 (14.5%) were removed after completion of treatment. Staphylococcus aureus was the most frequently isolated organism, found in 8 (6.8%) patients. Underlying diagnosis (p < 0.001), chemotherapy regimen (p < 0.001), sensitivity to antibiotics (p = 0.01), and any complication (p < 0.001) were significant factors affecting the duration of port-a-cath use. None of these factors were significant on multivariate cox regression analysis.
CONCLUSIONS: The mean duration of port-a-cath use was almost one year. Infection was the most common complication leading to premature removal, followed by port thrombosis.

Entities:  

Mesh:

Year:  2014        PMID: 25390061     DOI: 10.3855/jidc.4155

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

Review 1.  Overview, prevention and management of chemotherapy extravasation.

Authors:  Firas Y Kreidieh; Hiba A Moukadem; Nagi S El Saghir
Journal:  World J Clin Oncol       Date:  2016-02-10

2.  Chemothorax: a rare cause of a transudative pleural effusion.

Authors:  Devin Kelly; David Geottman; Bipin Sarodia
Journal:  BMJ Case Rep       Date:  2015-12-10

Review 3.  Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman.

Authors:  Philomena C D'Souza; Shiyam Kumar; Annupam Kakaria; Rashid Al-Sukaiti; Khalid Al-Baimani; Rana S Hamid; Alok K Mittal; Muna Al-Balushi; Ikram A Burney; Mansour S Al-Moundhri
Journal:  Sultan Qaboos Univ Med J       Date:  2021-03-15

4.  Efficacy and clinical outcome of the port-a-cath in children: a tertiary care-center experience.

Authors:  Osama Bawazir; Elaf Banoon
Journal:  World J Surg Oncol       Date:  2020-06-19       Impact factor: 2.754

5.  Hemiplegia Following Fluid Administration Through an Implanted Venous Access Device: A Case Report.

Authors:  James Waymack; Christopher McDowell; Nida Feller; Sharon Kim
Journal:  Clin Pract Cases Emerg Med       Date:  2022-02

6.  Outcomes following port-a-catheter placement in the Medicare population.

Authors:  Syed I Khalid; Samantha Maasarani; Rachyl M Shanker; Aaron Lee Wiegmann; Rita Wu; Nicholas J Skertich; Samantha L Terranella; Laura DeCesare; Edie Y Chan
Journal:  Surg Open Sci       Date:  2020-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.